GBL Ear Drop is a combination pharmaceutical formulation containing Lidocaine (2.0% w/v), Beclometasone (0.025% w/v), Clotrimazole (1.0% w/v), and Gentamicin (0.3% w/v), designed for the management of various otic conditions. Lidocaine acts as a local anesthetic, providing rapid symptomatic relief from pain and discomfort associated with ear infections or inflammations. Beclometasone, a potent corticosteroid, exerts anti-inflammatory and immunosuppressive effects, reducing swelling, redness, and irritation within the ear canal. Clotrimazole, an antifungal agent, is effective against a broad spectrum of fungal pathogens, making this formulation suitable for fungal otitis externa. Gentamicin, an aminoglycoside antibiotic, targets a wide range of aerobic gram-negative and some gram-positive bacteria, addressing bacterial infections concurrently. The synergistic combination of these active ingredients allows comprehensive treatment of mixed infections involving bacterial and fungal pathogens while alleviating inflammatory symptoms and pain. GBL Ear Drop is indicated for otitis externa, otomycosis, and other inflammatory ear conditions where polymicrobial infection is suspected. It should be used under medical supervision, with caution in patients with known hypersensitivity to any component. Proper administration and adherence to prescribed dosage are essential to ensure therapeutic efficacy and minimize potential adverse effects.